登录新浪财经APP 搜索【信披】查看更多考评等级 新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市 公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中心服务手册】 事件关联主体：福能东方、贵州百灵 事件类型：负面 ESG事件议题：G——财务信息虚假记载、信息披露重大遗漏 贵州百灵的问题更为严重，不仅跨2019年、2020年、2021年、2023 年四年财务造假，还未以权责发生 制为基础，按照收入成本费用配比原则确认当期销售费用，导致2019年至2021年期间少计销售费用，通 过违规确认销售费用累计虚增利润超 6.5 亿元、虚减利润超 4.5 亿元。 此次舆情事件，均指向公司内部治理与财务内控体系的失效。福能东方涉及营业收入、利润总额等多类 财务指标的虚假记载，直接影响投资者对公司真实经营状况的判断；贵州百灵的问题更为系统。这种根 据"需要"调节利润的行为，不仅违背会计准则，更暴露了公司治理中监督机制形同虚设、内部控制严重 缺失的问题。 值得注意的是，此类财务造假并非个例。根据新浪财经转载发布的《2025 年二季度上市公司 ESG 风险 报告》（数据来源 ...

当前，我国糖尿病药物市场正快速扩容。"糖宁通络"保密专利的受理恰逢其时，为我国糖尿病治疗领域 注入了民族医药的创新力量。若最终获得授权，"糖宁通络"将是我国首个获得保密专利的糖尿病治疗类 中药制剂，在有效避免核心技术外泄的同时，也将进一步加快其在临床推广、市场转化等方面的步伐， 有望成为改变我国乃至全世界糖尿病治疗格局的关键药物，为亿万患者带来全新选择。 姜伟董事长表示，作为全国苗药龙头企业，公司始终致力于通过现代科技手段挖掘苗药独特价值，"糖 宁通络"的研发正是民族医药传承与创新的生动实践。此次保密专利的受理，是国家对民族医药创新成 果的认可，也是国家对重大慢性疾病防治技术自主可控的战略考量。公司将进一步加快"糖宁通络"的临 床试验与产业转化进程，力争早日惠及全球患者，为人类健康贡献更多百灵力量。（CIS） 1月14日，贵州百灵披露公告，公司基于"糖宁通络"多年研究技术形成的"一种治疗糖尿病或其并发症的 中药制剂"，申请国家保密专利已获得国家知识产权局受理。保密保护范围涵盖配方组成、生产工艺及 多个治疗范围，保密期限与《中华人民共和国国家保密法》中"机密"保密期限相同。 "糖宁通络"是贵州百灵在长期挖掘和传 ...

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. (ST BaiLing) has applied for a national confidential patent for a traditional Chinese medicine formulation, "Tang Ning Tong Luo," aimed at treating diabetes and its complications, marking a significant milestone in the field of traditional Chinese medicine [1][2] Group 1: Company Developments - The confidential patent application for "Tang Ning Tong Luo" has been accepted by the National Intellectual Property Administration, highlighting the research achievements of the company [1] - "Tang Ning Tong Luo" is the first traditional Chinese medicine formulation in China to receive a confidential patent application, indicating its unique value in treating type 2 diabetes and its complications [2] - The patent protection will cover a range of conditions related to diabetes, including diabetic retinopathy, diabetic foot disease, erectile dysfunction associated with diabetes, and diabetic kidney disease, providing comprehensive protection throughout the disease cycle [2] Group 2: Industry Context - Diabetes has become a major public health challenge globally, with the International Diabetes Federation (IDF) reporting that by 2024, there will be 589 million diabetes patients aged 20-79 worldwide, with China having the highest number at 148 million [1] - The global market for diabetes treatment drugs is substantial, yet the core areas are still dominated by foreign manufacturers, and effective treatment options for complications remain scarce [1]

格隆汇1月14日丨ST百灵(002424.SZ)公布，近日收到国家知识产权局出具的《专利申请受理通知书》， 发明创造名称：一种治疗糖尿病或其并发症的中药制剂。本次国家知识产权局受理的"一种治疗糖尿病 或其并发症的中药制剂"国家保密专利申请，是基于公司糖宁通络项目多年研究所形成的专利技术。保 密保护范围涵盖配方组成、生产工艺及多个治疗范围，保密期限与《中华人民共和国国家保密法》 中"机密"保密期限相同。此次保密专利的受理，将为公司糖宁通络提供全方位且更严密的核心知识产权 保护。若最终获得专利授权，公司糖宁通络项目将在有效避免核心技术外泄的同时，进一步加快其在临 床推广、市场转化等方面的步伐，增强公司核心竞争力。 ...

Core Viewpoint - ST Bailin (002424.SZ) has received a patent application acceptance notice from the National Intellectual Property Administration for a traditional Chinese medicine formulation aimed at treating diabetes and its complications, which will enhance the company's core intellectual property protection [1] Group 1: Patent Application Details - The accepted patent application is for a "traditional Chinese medicine formulation for treating diabetes or its complications," based on years of research from the company's Tang Ning Tong Luo project [1] - The confidentiality protection scope includes formula composition, production processes, and multiple treatment areas, with a confidentiality period aligned with the "secret" confidentiality period under the National Confidentiality Law of the People's Republic of China [1] Group 2: Implications for the Company - The acceptance of this confidential patent will provide comprehensive and tighter core intellectual property protection for the Tang Ning Tong Luo project [1] - If the patent is ultimately granted, it will help the company avoid core technology leakage and accelerate clinical promotion and market transformation, thereby enhancing the company's core competitiveness [1]

证券代码：002424 证券简称：ST 百灵 公告编号：2026-001 贵州百灵企业集团制药股份有限公司 关于获得专利申请受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）近日收 到国家知识产权局出具的《专利申请受理通知书》，具体情况如下： 一、专利申请受理通知书内容 申请号：202610042695.2 2026 年 1 月 14 日 发明创造名称：一种治疗糖尿病或其并发症的中药制剂 二、专利背景 本次国家知识产权局受理的"一种治疗糖尿病或其并发症的中药 制剂"国家保密专利申请，是基于公司糖宁通络项目多年研究所形成 的专利技术。保密保护范围涵盖配方组成、生产工艺及多个治疗范围， 保密期限与《中华人民共和国国家保密法》中"机密"保密期限相同。 此次保密专利的受理，将为公司糖宁通络提供全方位且更严密的核心 知识产权保护。若最终获得专利授权，公司糖宁通络项目将在有效避 免核心技术外泄的同时，进一步加快其在临床推广、市场转化等方面 的步伐，增强公司核心竞争力。 三、风险提示： 本次专利申请处于受理 ...

贵州百灵公告称，公司近日收到国家知识产权局出具的《专利申请受理通知书》。受理的专利申请号为 202610042695.2，发明创造名称是"一种治疗糖尿病或其并发症的中药制剂"。该申请基于公司糖宁通络 项目多年研究形成的专利技术，若获授权，将为项目提供更严密知识产权保护。不过，此次申请处于受 理环节，存在无法通过审查并获授权的风险，且目前不会对公司经营产生重大影响。 ...

Core Viewpoint - Guizhou Securities Regulatory Bureau has intensified its crackdown on financial fraud, with significant penalties imposed on companies and individuals involved in fraudulent activities, aiming to purify the capital market environment and enhance regulatory effectiveness [1][2][5]. Group 1: Regulatory Actions - In 2025, Guizhou Securities Regulatory Bureau conducted inspections on 111 companies, implementing 31 administrative regulatory measures and 63 daily regulatory measures [1]. - Two financial fraud cases were severely punished, with a total of 1.94 billion yuan in penalties proposed against two listed companies and 20 responsible individuals, including 10-year market bans for four individuals [1][2]. - The bureau has adopted a "zero tolerance" policy towards financial fraud, emphasizing comprehensive punitive measures against violators [1]. Group 2: Specific Cases of Financial Fraud - The Guizhou Bailin financial fraud case involved the company underreporting sales expenses, leading to a cumulative profit inflation of 655 million yuan from 2019 to 2021, with a proposed fine of 25.6 million yuan and a 10-year market ban for the chairman [1][2]. - The *ST Gaohong case involved fraudulent activities that inflated revenue and profits, resulting in a proposed fine of 160 million yuan and market bans for three individuals [2]. Group 3: Strengthening Daily Supervision - The bureau has enhanced daily supervision across various sectors, focusing on issues such as insider trading, financial misreporting, and improper information disclosure [2][3]. - Specific measures included inspections of 10 companies, with 4 administrative and 10 daily regulatory actions taken [2]. Group 4: Oversight of Intermediary Institutions - Increased scrutiny on intermediary institutions, including underwriters and audit firms, to ensure compliance and accountability in financial reporting [3][4]. - The bureau has conducted inspections on 28 securities and futures institutions, implementing 1 administrative and 29 daily regulatory measures to ensure proper operations [4]. Group 5: Future Regulatory Focus - The bureau plans to continue enhancing regulatory effectiveness, focusing on major fraud cases and ensuring investor protection while promoting high-quality market development [5].

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, following the issuance of a notice of investigation [1][5] Summary by Sections Investigation Details - The company has received a notice of investigation from the CSRC and is currently being investigated for potential violations of information disclosure regulations [1][5] - A lawyer from Shanghai Baiyue Law Firm indicated that affected investors may have the right to file lawsuits for compensation once the CSRC's investigation concludes [1][5] Compensation Conditions - Investors who traded Guizhou BaiLing stock (002424) during specific periods and incurred losses may qualify for preliminary compensation registration: - Those who bought shares between April 30, 2020, and April 30, 2024, and held or sold at a loss after April 30, 2024 [2][6] - Those who bought shares between April 23, 2022, and April 30, 2024, and held or sold at a loss after April 30, 2024 [2][6] - The final compensation conditions will be determined by the formal administrative penalty decision from the CSRC and the effective ruling from the people's court [2][6] Required Documentation for Compensation - To initiate the compensation process, investors typically need to prepare the following documents: - Original transaction statements for Guizhou BaiLing stock, stamped by the brokerage firm [3][6] - A copy of the investor's ID (or business license for institutional investors) [4][7] - A confirmation of the securities account information from the brokerage [4][7]

Core Viewpoint - The article discusses the financial fraud case of Guizhou BaiLing, highlighting the importance of analyzing financial statements and identifying potential fraud signals beyond just the numbers reported in financial statements [4][8]. Financial Fraud Case Analysis - Guizhou BaiLing was found to have false disclosures in its annual reports for 2019, 2020, 2021, and 2023, with a total of 655 million yuan in sales expenses understated from 2019 to 2021, leading to inflated profits, and an additional 459 million yuan in sales expenses overstated in 2023, resulting in reduced profits [4][6]. - The methods used by Guizhou BaiLing involved adjusting sales expenses to manipulate current profits, which raises questions about the reliability of financial data [4][5]. Comparative Analysis with Peers - Guizhou BaiLing's core characteristics include being primarily engaged in traditional Chinese medicine manufacturing and OTC products, with key competitors being Jiangzhong Pharmaceutical, Kang En Bei, and Jichuan Pharmaceutical [4][5]. - Sales expenses for Guizhou BaiLing increased from 7.8 million yuan in 2017 to 12.9 million yuan in 2021, with a sales expense ratio rising from 30.2% to 41.4% during the same period, indicating a trend but not necessarily an anomaly [6][7]. Fraud Signal Analysis Framework - The analysis framework for identifying financial fraud includes three dimensions: business abnormal signals, financial abnormal signals, and governance warning signals [9][10]. - Governance warning signals are particularly emphasized, with a focus on abnormal behaviors of controlling shareholders and management, as well as market anomalies [11][12]. Governance Warning Signals - Abnormal behavior of controlling shareholders, such as high share pledges or legal disputes, can indicate potential financial manipulation pressures [13][19]. - The case of Guizhou BaiLing highlights the controlling shareholder's financial distress, which led to a "rescue fund" agreement to stabilize the company, raising concerns about potential financial reporting manipulation [19][20]. Market Abnormal Signals - Market abnormal signals include rumors, internal control failures, regulatory inquiries, and accounting errors, all of which were present in Guizhou BaiLing's case [21][29]. - Guizhou BaiLing received multiple inquiries from the Shenzhen Stock Exchange regarding financial data anomalies and internal control issues, which serve as critical warning signs [29][30]. Conclusion - The Guizhou BaiLing case illustrates that financial fraud signals can be detected through careful analysis of governance and market behaviors, emphasizing the need for vigilance in financial reporting [33][34].